C-4' modified adenosine kinase inhibitors

Details C-4' modified adenosine kinase inhibitors C-4' modified adenosine kinase inhibitors

C - Chemistry, Metallurgy

07

H

C07H 19/14 (2006.01) C07H 19/04 (2006.01) C07H 19/06 (2006.01) C07H 19/23 (2006.01)

Patent

CA 2220642

This invention relates to adenosine kinase inhibitors and to nucleoside analogs, C-4' modified pyrrolo[2,3-d] pyrimidine and pyrazolo[3,4-d] pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

Cette invention se rapporte à des inhibiteurs de l'adénosine kinase et à des analogues nucléosidiques, à savoir, des analogues nucléosidiques de pyrrolo[2,3-d] pyrimidine et pyrazolo[3,4-d] pyrimidine modifiés en C-4' ayant une activité d'inhibiteurs de l'adénosine kinase. L'invention se rapporte à des analogues nucléosidiques de ce type ne portant pas de substituants ou portant deux substituants en position C-4' de la fraction furanose (sucre). L'invention se rapporte également à la préparation et à l'utilisation des inhibiteurs de l'adénosine kinase dans le traitement de maladies cardio-vasculaires et d'accidents vasculaires cérébraux, d'inflammations et d'autres maladies qui peuvent être gérées par l'augmentation de la concentration locale d'adénosine.

Affiliated with

Also associated with

Rating

C-4' modified adenosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C-4' modified adenosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-4' modified adenosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1426068